Objectives: The purpose of this randomized study was to determine whether a strategically
chosen standardized set of programmable settings is at least as effective as physician …

Background—The benefit of novel implantable cardioverter defibrillator (ICD) programming
in reducing inappropriate ICD therapy and mortality was demonstrated in Multicenter …

Aims Absolute risk reduction (ARR) and number needed to treat (NNT) are considered by
many to be the most appropriate figures to use for the informed consent process, yet the …

Background: Defibrillation testing is often performed to establish effective arrhythmia
termination, but predictors and consequences of an inadequate defibrillation safety margin …

The new 2021 guidelines of the European Society of Cardiology (ESC) for the diagnosis and
treatment of acute and chronic heart failure include a new terminology for heart failure (HF) …

Aims The benefit of prophylactic implantable cardioverter-defibrillator (ICD) is not uniform
due to differences in the risk of life-threatening ventricular tachycardia (VT)/ventricular …

The implantable cardioverter defibrillator (ICD) has emerged as an important treatment
option for selected patients who are at risk of sudden cardiac death. Randomized trials have …

Background: In clinical trials, manufacturer-specific, strategic programming of implantable
cardioverter–defibrillators (ICDs), including faster detection rates, reduces unnecessary …

Background Every 4–7 years an implantable cardioverter defibrillator (ICD) pulse generator
must be replaced surgically. This procedure is not without risk. In some cases, the risk …

Background—Although implantable cardioverter-defibrillators (ICDs) reduce mortality in
primary prevention patients with left ventricular systolic dysfunction, recent studies have …